Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06881836 · ClinicalTrials.gov registry record · Phase 2

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

A Phase 2 study of Alzheimer Disease, sponsored by Ono Pharmaceutical Co..

Active
Registry status
Phase 2
Development phase
240
Enrollment target
20
Study locations

NCT06881836 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Ono Pharmaceutical Co.. The registered enrollment target is 240 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06881836, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Ono Pharmaceutical Co..

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Placebo
  • DRUG ONO-2020

Study Locations (20)

Florida

  • Brain Matters Research - Delray Beach
  • Velocity Clinical Research, Hallandale Beach - Hallandale
  • Premier Clinical Research Institute; Inc. - Miami
  • Quantum Clinical Trials - Miami Beach
  • Suncoast Clinical Research - New Port Richey
  • Renstar Medical Research - Ocala
  • Charter Research - Orlando - Orlando
  • Accel Research Sites - Brain and Spine Institute - Port Orange
  • USF Health Byrd Alzheimer's Institute - Tampa
  • ForCare Clinical Research - Tampa

Arizona

  • Banner Alzheimer's Institute (BAI) - Phoenix
  • Clinical Endpoints - Scottsdale
  • Banner Sun Health Research Institute - Sun City
  • Center for Neurosciences-Research - Tucson

California

  • Profound Research LLC at The Neurology Center of Southern California - Carlsbad
  • Neurology Center of North Orange County - Fullerton
  • Stanford University - Palo Alto
  • Sunwise Clinical Research - Walnut Creek

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • CenExel Rocky Mountain Clinical Research - Englewood

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2025-04-24
Est. Completion 2026-08
Phase Phase 2

Sponsor

Ono Pharmaceutical Co.

17 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06881836

The ClinicalTrials.gov registry entry for NCT06881836 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower). The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06881836 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06881836 about?

NCT06881836 is a clinical study titled "A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease". This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, m...

What is the current status of trial NCT06881836?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-04-24. Estimated completion is 2026-08.

What conditions does trial NCT06881836 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT06881836?

The interventions under investigation include: Placebo (DRUG), ONO-2020 (DRUG).

Who is sponsoring clinical trial NCT06881836?

This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06881836 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.